The independent journey of CureVac on public markets has concluded. The Nasdaq exchange has suspended trading of the ...
CureVac ( ($CVAC) ) just unveiled an update. On January 6, 2026, CureVac N.V. completed a post-offer reorganization tied to BioNTech SE’s exchange ...
An update from BioNTech SE ( ($BNTX) ) is now available. On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously ...
Evotec SE has created a new Executive Vice President role that combines Global Communications and Investor Relations as part of a broader effort to strengthen strategic clarity and stakeholder ...
The curtain is falling on CureVac's time as a publicly traded entity. Following the successful takeover bid by BioNTech, the company's share price has effectively decoupled from broader market ...
CureVac's stock has entered a period of exceptionally low volatility, with its price movement now tightly constrained. This trading pattern reflects a market that has fully priced in the company's ...
BioNTech has completed its exchange offer to acquire CureVac Acquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing ...
In total, approximately 86.75% of CureVac shares were tendered; BioNTech expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously ...
BioNTech has completed its exchange offer to acquire CureVac Acquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback